XTL Biopharmaceuticals Ltd.
XTLB
Price:
$2.13
Market Cap:
$5.80M
XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to identifying and advancing novel drug therapies for autoimmune conditions. Its primary investigational compound, hCDR1, is poised to enter Phase II trials, specifically targeting systemic lupus erythematosus and Sjogren's syndrome. The company holds a crucial licensing agreement with Yeda Research and Development Company Limited, which grants rights for the research, development, and eventual commercialization of hCDR1 across multiple therapeutic indications. Originally established in 1993 as Xenograft Technologies Ltd., the company rebranded to XTL Biopharmaceuticals Ltd. in July 1995. It operates from its headquarters in R...[Read more]
Industry
Biotechnology
IPO Date
2005-09-01
Stock Exchange
NASDAQ
Ticker
XTLB
PE Ratio
[-0.59]
ROE
[-26.83%]
Current Ratio
[0.61]
Dividend Yield
[0%]
Enterprise Value
[5.57M]
Dividend History
The ROE as of June 2026 (TTM) for XTL Biopharmaceuticals Ltd. (XTLB) is -26.83%
According to XTL Biopharmaceuticals Ltd.’s latest financial reports and current stock price. The company's current ROE is -26.83%. This represents a change of 283.84% compared to the average of -6.99% of the last 4 quarters.
XTL Biopharmaceuticals Ltd. (XTLB) Historical ROE (quarterly & annually)
How has XTLB ROE performed in the past?
The mean historical ROE of XTL Biopharmaceuticals Ltd. over the last ten years is -25.41%. The current -26.83% ROE has changed 5.59% with respect to the historical average. Over the past ten years (40 quarters), XTLB's ROE was at its highest in in the September 2017 quarter at 43.81%. The ROE was at its lowest in in the June 2017 quarter at -66.41%.
Average
-25.41%
Median
-20.44%
Minimum
-94.72%
Maximum
35.88%
XTL Biopharmaceuticals Ltd. (XTLB) ROE by Quarter and Year
Discovering the peaks and valleys of XTL Biopharmaceuticals Ltd. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 23.44%
Maximum Annual ROE = 35.88%
Minimum Annual Increase = -513.26%
Minimum Annual ROE = -94.72%
| Year | ROE | Change |
|---|---|---|
| 2024 | -18.90% | 23.44% |
| 2023 | -0.08% | -99.76% |
| 2022 | -33.71% | -513.26% |
| 2021 | 8.16% | -137.68% |
| 2020 | -21.65% | 12.19% |
| 2019 | -19.30% | -153.78% |
| 2018 | 35.88% | -266.26% |
| 2017 | -21.58% | -77.22% |
| 2016 | -94.72% | 7.37% |
| 2015 | -88.21% | 62.67% |
XTL Biopharmaceuticals Ltd. (XTLB) Average ROE
How has XTLB ROE performed in the past?
The current ROE of XTL Biopharmaceuticals Ltd. (XTLB) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-17.56%
5-year avg
-13.24%
10-year avg
-25.41%
XTL Biopharmaceuticals Ltd. (XTLB) ROE vs. Peers
How is XTLB’s ROE compared to its peers?
XTL Biopharmaceuticals Ltd.’s ROE is greater than Cyclerion Therapeutics, Inc. (-62.10%), greater than Polyrizon Ltd. (-26.12%), greater than VYNE Therapeutics Inc. (-69.57%), greater than Alaunos Therapeutics, Inc. (-165.94%), less than AIM ImmunoTech Inc. (261.84%), greater than Quoin Pharmaceuticals, Ltd. (-292.33%), greater than Pasithea Therapeutics Corp. (-57.44%), greater than KALA BIO, Inc. (-1335.64%), greater than Radiopharm Theranostics Limited (-93.08%), greater than Ensysce Biosciences, Inc. (-631.47%),
| Company | ROE | Market cap |
|---|---|---|
| -62.10% | $14.07M | |
| -26.12% | $12.47M | |
| -69.57% | $10.81M | |
| -165.94% | $5.52M | |
| 261.84% | $1.38M | |
| -292.33% | $8.43M | |
| -57.44% | $4.40M | |
| -1335.64% | $57.68M | |
| -93.08% | $5.50M | |
| -631.47% | $2.33M |
Build a custom stock screener for XTL Biopharmaceuticals Ltd. (XTLB) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like XTL Biopharmaceuticals Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
XTL Biopharmaceuticals Ltd. (XTLB) and other stocks custom spreadsheet templates
The easiest way to analyze a company like XTL Biopharmaceuticals Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is XTL Biopharmaceuticals Ltd.'s ROE?
How is the ROE calculated for XTL Biopharmaceuticals Ltd. (XTLB)?
What is the highest ROE for XTL Biopharmaceuticals Ltd. (XTLB)?
What is the 3-year average ROE for XTL Biopharmaceuticals Ltd. (XTLB)?
What is the 5-year average ROE for XTL Biopharmaceuticals Ltd. (XTLB)?
How does the current ROE for XTL Biopharmaceuticals Ltd. (XTLB) compare to its historical average?